What changed in Viatris Inc.'s latest annual report
In the year ended 31 Dec 2025, Viatris Inc.'s revenue fell 3% to USD 14.25bn, from USD 14.69bn; cash and cash equivalents rose 80% to USD 1.32bn, from USD 734.80m; long-term debt fell 11.1% to USD 12.48bn, from USD 14.04bn.
Year ended 31 Dec 2025. Source: 10-K filed 26 Feb 2026, read it on SEC EDGAR.
USD 14.69bn to USD 14.25bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 14.69bn | 14.25bn | Down 3% |
| Total assets | 41.50bn | 37.19bn | Down 10.4% |
| Total liabilities | 22.87bn | 22.48bn | Down 1.7% |
| Long-term debt | 14.04bn | 12.48bn | Down 11.1% |
| Cash and cash equivalents | 734.80m | 1.32bn | Up 80% |
Questions people ask
Did Viatris Inc.'s revenue grow last year?
Revenue fell 3%, from USD 14.69bn to USD 14.25bn in the year ended 31 Dec 2025.
How much cash and debt does Viatris Inc. have?
At its latest year end (31 Dec 2025), Viatris Inc. reported cash and cash equivalents of USD 1.32bn and long-term debt of USD 12.48bn.
Where do these numbers come from?
From Viatris Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Viatris Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%